Low-dose cytarabine: persistence of a clonal abnormality during complete remission of acute nonlymphocytic leukemia.

[1]  A. Cork,et al.  Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. , 1985, Cancer genetics and cytogenetics.

[2]  M. Tomonaga,et al.  Low‐dose cytosine arabinoside regimen induced a complete remission with normal karyotypes in a case with hypoplastic acute myeloid leukaemia with No. 8‐trisomy: in vitro and in vivo evidence for normal haematopoietic recovery , 1985, British journal of haematology.

[3]  F. Sigaux,et al.  Low‐dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients , 1985, Cancer.

[4]  D. Hossfeld,et al.  Low-dose cytarabine: chromosomal findings suggesting its cytostatic as well as differentiating effect. , 1985, Leukemia research.

[5]  J. Singer,et al.  A clonal complete remission in a patient with acute nonlymphocytic leukemia originating in a multipotent stem cell. , 1984, The New England journal of medicine.

[6]  J. Griffin,et al.  Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. , 1983, The New England journal of medicine.

[7]  J. Griffin,et al.  Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. , 1982, Experimental hematology.

[8]  M. Housset,et al.  Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells? , 1982, British journal of haematology.

[9]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.